Zenas BioPharma, Financial Statements From 2010 to 2024
| ZBIO Etf | USD 10.01 0.25 2.56% |
Check Zenas BioPharma, financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Zenas BioPharma,'s main balance sheet or income statement drivers, such as , as well as many indicators such as . Zenas financial statements analysis is a perfect complement when working with Zenas BioPharma, Valuation or Volatility modules.
Zenas |
Zenas BioPharma, Common ETF Beta Analysis
Zenas BioPharma,'s Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current Zenas BioPharma, Beta | -2.35 |
Most of Zenas BioPharma,'s fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Zenas BioPharma, Common is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
| Competition |
In accordance with the recently published financial statements, Zenas BioPharma, Common has a Beta of -2.35. This is much lower than that of the Biotechnology family and significantly lower than that of the Health Care category. The beta for all United States etfs is notably higher than that of the company.
About Zenas BioPharma, Financial Statements
Zenas BioPharma, investors utilize fundamental indicators, such as revenue or net income, to predict how Zenas Etf might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
The investment seeks daily investment results, before fees and expenses, that correspond to three times the inverse of the daily performance of the NASDAQ Biotechnology Index. ProShares UltraPro is traded on NGM Exchange in the United States.
Pair Trading with Zenas BioPharma,
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Zenas BioPharma, position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Zenas BioPharma, will appreciate offsetting losses from the drop in the long position's value.Moving together with Zenas Etf
Moving against Zenas Etf
| 0.85 | VAXX | Vaxxinity | PairCorr |
| 0.69 | EPRX | Eupraxia Pharmaceuticals | PairCorr |
| 0.65 | FRTX | Fresh Tracks Therapeutics | PairCorr |
| 0.63 | GRCE | Grace Therapeutics, Symbol Change | PairCorr |
| 0.62 | CEROW | CERo Therapeutics Symbol Change | PairCorr |
The ability to find closely correlated positions to Zenas BioPharma, could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Zenas BioPharma, when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Zenas BioPharma, - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Zenas BioPharma, Common to buy it.
The correlation of Zenas BioPharma, is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Zenas BioPharma, moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Zenas BioPharma, Common moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Zenas BioPharma, can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Zenas Etf
Zenas BioPharma, financial ratios help investors to determine whether Zenas Etf is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Zenas with respect to the benefits of owning Zenas BioPharma, security.